Efficacy of Combination Therapy Sofosbuvir Plus Velpatasvir in Treatment of Hepatitis C Virus(HCV)

Abstract

Objective: To assess the treatment response and tolerance in HCVpatients without doing genotypes.
Method: An interventional study was conducted to evaluate the efficacy and sustained virologic response  (SVR) of 200 patients suffering with hepatitis C after an intervention of once-daily Sofosbuvir 400 mg plus  Velpatasvir 100 mg for 12 weeks at Akhtar Saeed Trust hospital and Farooq Hospital Lahore between December 2019 to December 2021.The sample size was calculated by using keeping margin of error at 5%, confidence level at 95%, population size 20000 and response rate at 30%. Patients were followed up on
weekly basis with CBC, LFTS and RFTS and HCVRNAby PCR at 4th week and six months after completion  of 12 weeks treatment. With SPSS 23, Chi square test was applied and p-value of < 0.05 was considered  significant.
Results: In this interventional study out of 200 hepatitis C positive patients 139(63.5%) were males and  61(27.9%) were females. A significant association was observed between gender (p=0.000), presenting  complaints (p =0.002) abdominal ultrasound findings (0.004), status of patient (p=0.015), comorbidities (p=  0.042) and lab investigations (p=0.000). Various side effects were reported by 69(31.5%) experienced  headaches, 60(27.4%) experienced dyspepsia, 57(26%) experienced nausea as a result of this combination
therapy.
Conclusion: Twelve weeks of treatment with combination therapy of sofosbuvir and Velpstasvir is well  tolerated and has high SVR in HCVpatients with all types of genotypes.

How to cite: Latif S, Qaisar W, Saleem HQB, Waseem T, Khan ZH. Efficacy of Combination Therapy Sofosbuvir Plus Velpatasvir
in Treatment of HCV. Esculapio - JSIMS 2022;18(03).